Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and Development

Kanvas Biosciences, a Pangaea Ventures portfolio company focused on microbiome drug discovery and development, has published new research on its High-Phylogenetic-Resolution Spatial Mapping (HiPR-Map) Platform spectral imaging technology. This novel tool promises to transform how researchers visualize and analyze the complexities of the microbiome.

The spectral imaging platform offers unprecedented insights into the spatial organization and interactions within microbial communities. By providing a detailed understanding of these intricate ecosystems, Kanvas Bio aims to accelerate the development of new therapeutics targeting a range of diseases.

Read the full press release to learn more.